Redefining Expectations
in Rare Disease

On February 26, Bradley Campbell, President and CEO, Amicus Therapeutics, delivered testimony before the U.S. Senate Special Committee On Aging.
The full written testimony is available to read here.

About Amicus

We are a leading, global rare-disease focused biotechnology company with a clear and compelling mission: to develop and deliver transformative medicines for people living with rare diseases.

We are guided by people living with rare diseases across the globe.

Get to know some of them:

Lisa, Age 57

Living with Fabry Disease

Kody, Age 43

Living with Pompe Disease

Hiroki, Age 26